Atul Pande

Director at Karuna Therapeutics

Dr. Pande is a physician who qualified in medicine, and specialized in psychiatry, at the University of Lucknow in India. He obtained additional specialty training at Western University in Canada, and subsequently served on the faculty of the University of Michigan Medical School. Over nearly thirty years of his academic and industry career, Dr. Pande has been involved in the development of important central nervous system drugs while holding various senior roles in GlaxoSmithKline, Pfizer, Parke-Davis/Warner-Lambert, and Lilly Research Laboratories. His experience includes drug development, registration, launch and lifecycle management in the areas of anxiety, depression, epilepsy, neuropathic pain, schizophrenia, traumatic brain injury, and Alzheimer’s and Parkinson’s diseases, and others. Dr. Pande currently serves as Senior Advisor to PureTech Health; non-executive director of Autifony Therapeutics; lead independent director of Axovant Gene Therapies (NASDAQ:AXGT); scientific advisory to Cennerv Pharma; development consultant to various companies; and as President and CEO of Verity BioConsulting. Dr. Pande is a fellow of several professional societies, including the American Psychiatric Association. He has published over 50 peer-reviewed scientific papers and over 100 abstracts, book chapters, and book reviews.


  • Director

    Current role

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.